Roivant Sciences
https://roivant.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Roivant Sciences
Myovant’s Relugolix Won’t Be Stopped By Missed Endpoint
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
J&J Seeks Command Position In FcRn Space With Momenta Buyout
J&J will pay about $6.5bn to acquire Momenta and its potential “pipeline in a pathway” with nipocalimab. Analysts expect this deal may lead to further M&A activity in the anti-FcRn space.
Finance Watch: New Funding Available For Antibacterials, Start-Ups
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Altavant Sciences
- Alyvant
- Aruvant Sciences
- Axovant Sciences
- Cyotvant Sciences
- Datavant
- Dermavant Sciences
- Enzyvant
- Genevant
- Immunovant Sciences
- Metavant Sciences
- PhaseRx
- Respivant
- Roivant Health
- Roivant Neurosciences Ltd
- Roivant Pharma
- Roivant Sciences Ltd.
- Inc.
- Sinovant Sciences
- Sumitovant Biopharma Ltd.
- Valor Biotechnology